With our results in GBM and previous studies from prostate cancer showing specific cancer stem cell suppression, AR antagonists could be good therapeutic candidates and repurposed in the treatment of GBM, particularly when combined with current standard care modalities such as temozolomide and/or radiation therapy, which cancer stem cells are known to be resistant to (3, 86, 87). The gene discussed is AR; the disease is cancer.